KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Debt to Equity (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Debt to Equity data on record, last reported at $1.14 in Q3 2025.

  • For Q3 2025, Debt to Equity fell 12.55% year-over-year to $1.14; the TTM value through Sep 2025 reached $1.14, down 12.55%, while the annual FY2024 figure was $1.37, 99.91% up from the prior year.
  • Debt to Equity reached $1.14 in Q3 2025 per EBS's latest filing, down from $1.25 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.37 in Q4 2024 and bottomed at $0.32 in Q4 2022.
  • Average Debt to Equity over 5 years is $0.77, with a median of $0.61 recorded in 2021.
  • Peak YoY movement for Debt to Equity: tumbled 35.65% in 2022, then soared 147.36% in 2024.
  • A 5-year view of Debt to Equity shows it stood at $0.5 in 2021, then crashed by 35.65% to $0.32 in 2022, then soared by 112.77% to $0.69 in 2023, then skyrocketed by 99.91% to $1.37 in 2024, then dropped by 17.19% to $1.14 in 2025.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were $1.14 in Q3 2025, $1.25 in Q2 2025, and $1.2 in Q1 2025.